Designation of Arsenic Trioxide (Phenasen) as an orphan drug - Phebra Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Australian Parliament, was established to regulate therapeutic goods in Australia, ensuring their safety, quality, and efficacy. This Act was introduced to address the need for a robust framework governing the use of therapeutic products, including medicines, medical devices, and blood products. One significant aspect of this legislation is its ability to designate certain drugs as orphan drugs, which are designed to treat rare medical conditions. This designation is intended to encourage the development and availability of treatments for diseases that might otherwise be neglected due to their low prevalence. On 27 February 2017, the Therapeutic Goods Administration, acting under the authority delegated by the Secretary, designated Arsenic Trioxide (Phenasen) as an orphan drug for the treatment of Acute Promyelocytic Leukaemia (APL). This decision was made under subregulation 16J(2) of the Therapeutic Goods Regulations 1990, reflecting the policy objective of facilitating access to necessary treatments for rare conditions. The sponsor for this orphan drug designation is Phebra Pty Ltd, which aims to provide an effective treatment option for individuals suffering from APL.

Scope and Application

The Therapeutic Goods Act 1989, as amended, designates Arsenic Trioxide (Phenasen) as an orphan drug specifically for the treatment of Acute Promyelocytic Leukaemia (APL). This designation applies to Arsenic Trioxide (Phenasen) in its capsule form and is under the sponsorship of Phebra Pty Ltd. The Act’s application here is targeted at a specific therapeutic need, namely, the treatment of a rare and severe form of leukaemia, thereby focusing on unmet medical needs and encouraging the development and availability of treatments for rare diseases. This legislative action applies within the jurisdictional reach of the Commonwealth of Australia, overseen by the Therapeutic Goods Administration (TGA). The legislation does not detail any exclusions or exemptions specific to this designation, and its application is directly tied to the therapeutic indication and dosage form specified. The designation of orphan drugs is an extension of the Therapeutic Goods Act, utilising subordinate instruments within the Therapeutic Goods Regulations 1990 to provide clarity and specificity regarding the therapeutic use and development of such drugs.

Key Provisions

The main operative sections of this legislation, specifically the Therapeutic Goods Act 1989, pertain to the designation of certain therapeutic goods under the orphan drug category. Section 16J of the Therapeutic Goods Regulations 1990 allows for the designation of orphan drugs, which are medications intended for the treatment of rare diseases. In this instance, Arsenic Trioxide (Phenasen) is designated as an orphan drug for the treatment of Acute Promyelocytic Leukaemia (APL) (s. 16J(2)). The document specifies the dose form, which is a capsule, and identifies the sponsor, Phebra Pty Ltd. The obligations and requirements imposed by this Act on the parties involved are primarily centred around the designation process and the therapeutic benefits of the orphan drug. The Delegate of the Secretary, in this case, Dr. Anthony Gill, has the authority to designate orphan drugs under the Regulations. Phebra Pty Ltd, as the sponsor, must ensure that the orphan drug meets the necessary standards and criteria for designation. This includes providing evidence and data supporting the orphan drug’s efficacy and safety for the specified medical condition. Failure to comply with the requirements of the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 may result in various civil and criminal consequences. Offences under the Act can lead to substantial penalties, although the specific penalties are not detailed in the provided text. It is important for all parties involved to adhere strictly to the legislative and regulatory requirements to avoid any legal repercussions. The consequences of non-compliance can range from administrative penalties to more severe criminal charges, depending on the nature and severity of the breach.